var data={"title":"Cutaneous T cell pseudolymphomas","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cutaneous T cell pseudolymphomas</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/contributors\" class=\"contributor contributor_credentials\">Rein Willemze, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/contributors\" class=\"contributor contributor_credentials\">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 11, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H373511903\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term cutaneous pseudolymphoma refers to a heterogeneous group of benign skin disorders that simulate cutaneous lymphomas histologically and sometimes clinically. Cutaneous pseudolymphomas can be separated into two major subtypes, pseudolymphomas mimicking a cutaneous B cell lymphoma and pseudolymphomas mimicking a cutaneous T cell lymphoma (<a href=\"image.htm?imageKey=DERM%2F102613\" class=\"graphic graphic_table graphicRef102613 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>Histologically, cutaneous T cell pseudolymphomas may show a superficial band-like pattern simulating early <span class=\"nowrap\">patch/plaque-stage</span> mycosis fungoides (MF) or a nodular or diffuse pattern simulating peripheral T cell lymphoma, not otherwise specified (PTCL, NOS) or tumor-stage MF. Examples of the first category include lymphomatoid contact dermatitis, lymphomatoid drug eruptions, and actinic reticuloid; examples of the second category include persistent arthropod reactions and nodular scabies. However, in most cases the cause is unknown. Such idiopathic cutaneous pseudo-T-cell lymphomas may have a band-like superficial pattern or a nodular or diffuse pattern.</p><p>This topic will focus on distinct clinicopathologic entities commonly included in the spectrum of cutaneous T cell pseudolymphomas. Other mimickers of early-stage MF or primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders, as well as HIV- and other immunodeficiency-related CD8<sup>+</sup> cutaneous pseudolymphomas will be briefly discussed. Cutaneous T cell lymphomas, lymphomatoid papulosis, and cutaneous B cell pseudolymphomas are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=classification-of-primary-cutaneous-lymphomas\" class=\"medical medical_review\">&quot;Classification of primary cutaneous lymphomas&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-sezary-syndrome\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=primary-cutaneous-t-cell-lymphomas-rare-subtypes\" class=\"medical medical_review\">&quot;Primary cutaneous T cell lymphomas, rare subtypes&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-systemic-anaplastic-large-cell-lymphoma\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lymphomatoid-papulosis\" class=\"medical medical_review\">&quot;Lymphomatoid papulosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cutaneous-b-cell-pseudolymphomas\" class=\"medical medical_review\">&quot;Cutaneous B cell pseudolymphomas&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H373512003\"><span class=\"h1\">ACTINIC RETICULOID</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Actinic reticuloid, also called chronic actinic dermatitis, is a severe photosensitivity reaction to UVB, UVA, and, in some cases, visible light with histologic features suggesting mycosis fungoides (MF) [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Actinic reticuloid is an extremely rare disorder and almost exclusively affects older adult men [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/5-7\" class=\"abstract_t\">5-7</a>]. Patients present with a pruritic, persistent eczematous dermatitis with prominent lichenification <span class=\"nowrap\">and/or</span> infiltrated papules and plaques involving sun-exposed skin areas (eg, face, neck, back of the hands, forearms, upper chest) (<a href=\"image.htm?imageKey=DERM%2F101492%7EDERM%2F101494\" class=\"graphic graphic_picture graphicRef101492 graphicRef101494 \">picture 1A-B</a>). (See <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment#H12594781\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Chronic actinic dermatitis'</a>.)</p><p class=\"headingAnchor\" id=\"H25276800\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologic examination of a skin biopsy shows eczematous features including acanthosis, spongiosis, and variably dense dermal infiltrates of lymphocytes, histiocytes, eosinophils, plasma cells, and multinucleated dendritic cells [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/5,6\" class=\"abstract_t\">5,6</a>]. These infiltrates contain atypical T cells with medium-sized to large cerebriform and hyperchromatic nuclei similar to those observed in MF and S&eacute;zary syndrome (<a href=\"image.htm?imageKey=DERM%2F103382\" class=\"graphic graphic_picture graphicRef103382 \">picture 2</a>). Exocytosis of atypical lymphocytes in the epidermis can be found.</p><p>In contrast to S&eacute;zary syndrome, most cases of actinic reticuloid show a CD8<sup>+</sup> T-cell phenotype (<a href=\"image.htm?imageKey=DERM%2F103383\" class=\"graphic graphic_picture graphicRef103383 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/5\" class=\"abstract_t\">5</a>]. Although there are reports of rare cases of erythrodermic CTCL with severe photosensitivity and a CD8<sup>+</sup> immunophenotype mimicking actinic reticuloid, progression of actinic reticuloid to CTCL is unlikely [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/6,8\" class=\"abstract_t\">6,8</a>].</p><p class=\"headingAnchor\" id=\"H373512039\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of actinic reticuloid is suspected in an older patient presenting with a persistent eczematous eruption affecting primarily the sun-exposed skin. The definitive diagnosis requires a skin biopsy for routine histology and immunophenotyping and the documentation of increased sensitivity (decreased MED) to UVB, often to UVB and UVA, and occasionally to visible light by phototesting [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/4,5,7\" class=\"abstract_t\">4,5,7</a>]. Patch testing and photopatch testing may reveal positive reactions to one or more allergens, in particular fragrances and sesquiterpene lactone mix, in a significant number of patients [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/2,5\" class=\"abstract_t\">2,5</a>]. (See <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment#H12594781\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Chronic actinic dermatitis'</a>.)</p><p class=\"headingAnchor\" id=\"H85106212\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunophenotyping and T-cell receptor gene rearrangement analysis are useful adjuncts to histopathologic examination to differentiate erythrodermic actinic reticuloid from S&eacute;zary syndrome. The latter is defined by the presence of clonal CD4<sup>+</sup> T cells in the skin and peripheral blood, with a CD4:CD8 ratio greater than 10 in most cases [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/9\" class=\"abstract_t\">9</a>]. In contrast, the skin infiltrates of actinic reticuloid show a predominant CD8<sup>+</sup> T-cell phenotype, and the peripheral blood often shows a low or even inverse CD4:CD8 ratio [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/5\" class=\"abstract_t\">5</a>]. Clonal T cells are not detected in skin or blood of patients with actinic reticuloid [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/6,10\" class=\"abstract_t\">6,10</a>]. (See <a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-sezary-syndrome\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H373512057\"><span class=\"h1\">LYMPHOMATOID CONTACT DERMATITIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In rare cases, allergic contact dermatitis may show histologic features simulating early-stage MF. Since the term was first coined in 1976, only 23 cases have been reported [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/11,12\" class=\"abstract_t\">11,12</a>].</p><p>Lymphomatoid contact dermatitis has been associated with various allergens, including metals (nickel sulphate, gold, cobalt), rubber chemicals, dyes, and preservatives. Patients present with pruritic erythematous patches or plaques that preferentially involve the abdomen, upper legs, and buttocks, as in early-stage MF [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/12\" class=\"abstract_t\">12</a>]. A generalized eruption is rare.</p><p>Histologic examination of a skin biopsy shows a superficial band-like infiltrate. The epidermis shows variable acanthosis and spongiosis and usually contains only few atypical T cells. Intraepidermal collections of Langerhans cells (CD1a<sup>+</sup>) and small T cells may be present, but should not be misinterpreted as true Pautrier's micro-abscesses as observed in MF. In rare cases, clonal T-cell receptor gene rearrangements have been detected, but in most cases a polyclonal T-cell population is present [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/12\" class=\"abstract_t\">12</a>].</p><p>A positive patch test to a relevant allergen and the resolution of the skin lesion with avoidance of the offending allergen confirms the diagnosis of lymphomatoid contact dermatitis.</p><p class=\"headingAnchor\" id=\"H373512063\"><span class=\"h1\">LYMPHOMATOID DRUG REACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymphomatoid drug eruptions are the most common mimickers of cutaneous T cell lymphomas. Based upon the clinical and histologic presentation, different types of lymphomatoid drug eruption can be distinguished:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug-induced pseudolymphoma syndrome (drug reaction with eosinophilia and systemic symptoms [DRESS] mimicking a cutaneous T cell lymphoma [CTCL])</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug reaction without systemic symptoms mimicking early-stage mycosis fungoides [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/13,14\" class=\"abstract_t\">13,14</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CD30<sup>+</sup> lymphomatoid drug reaction [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/15-18\" class=\"abstract_t\">15-18</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug reaction with the histologic features of a pseudo-B-cell lymphoma (uncommon) [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/19,20\" class=\"abstract_t\">19,20</a>]</p><p/><p>Lymphomatoid drug eruptions, including most cases of DRESS, usually resolve after withdrawal of the offending drug. Progression of lymphomatoid drug eruptions to true malignant lymphoma has been reported, but is exceptional.</p><p class=\"headingAnchor\" id=\"H57372718\"><span class=\"h2\">Drug-induced pseudolymphoma syndrome (DRESS mimicking CTCL)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several terms, including drug-induced pseudolymphoma syndrome, anticonvulsant hypersensitivity syndrome, or drug-induced hypersensitivity syndrome, have been used to indicate severe drug reactions characterized by the combination of a generalized rash, fever, lymphadenopathy, hematologic abnormalities (eosinophilia; presence of atypical lymphocytes), visceral involvement, and, in some cases, histologic features mimicking a cutaneous malignant lymphoma.</p><p>The term drug reaction with eosinophilia and systemic symptoms (DRESS) is now widely used for these severe drug reactions, whether or not they present with histologic features suspicious for cutaneous lymphoma. DRESS is most commonly caused by anticonvulsants, <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a>, sulfonamides, and antibiotics (<a href=\"image.htm?imageKey=DERM%2F86760\" class=\"graphic graphic_table graphicRef86760 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p>Some patients with DRESS may have clinical, histologic, and hematologic findings that raise suspicion of mycosis <span class=\"nowrap\">fungoides/S&eacute;zary</span> syndrome, such as erythroderma, high numbers of circulating S&eacute;zary cells, and highly increased CD4:CD8 ratios. However, clonal T-cell receptor gene rearrangements are detected only in a small minority of these cases [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/22-25\" class=\"abstract_t\">22-25</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 50 skin biopsies from 36 patients with DRESS, a lichenoid interphase dermatitis with atypical lymphocytes, sometimes resembling S&eacute;zary cells, was found in 14 [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/24\" class=\"abstract_t\">24</a>]. In most cases these cells had the phenotype of CD8<sup>+</sup>, granzyme B<sup>+</sup>-activated T cells. T-cell clonality was found in only one biopsy from a patient who also had a T-cell clone in the blood.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective study of 117 patients with DRESS, 67 percent had circulating atypical T cells [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug-induced pseudo-S&eacute;zary syndrome with S&eacute;zary cell counts higher than <span class=\"nowrap\">1000/mm<sup>3</sup>,</span> CD4:CD8 ratio more than 10, and identical clonal TCR gene rearrangements in skin and peripheral blood has been reported in a patient treated with a combination of <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a> and <a href=\"topic.htm?path=hydrochlorothiazide-drug-information\" class=\"drug drug_general\">hydrochlorothiazide</a> [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"headingAnchor\" id=\"H373512101\"><span class=\"h2\">Drug eruptions without systemic symptoms simulating CTCL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many different drugs have been reported to cause mycosis fungoides-like or CD30<sup>+</sup> lymphomatoid drug reactions with minimal or no systemic involvement. They include anticonvulsants, antidepressants, antihypertensives, beta blockers, calcium channel blockers, diuretics, antibiotics, non-steroidal antiinflammatory drugs, antihistamines, and biologics [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/2,15,26-29\" class=\"abstract_t\">2,15,26-29</a>].</p><p class=\"headingAnchor\" id=\"H373512107\"><span class=\"h3\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with lymphomatoid drug eruption without systemic involvement may develop a solitary or multiple erythematous nodules or plaques several months after the initiation of the offending drug (<a href=\"image.htm?imageKey=DERM%2F103512\" class=\"graphic graphic_picture graphicRef103512 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/14,25\" class=\"abstract_t\">14,25</a>]. Lesions usually resolve after withdrawal of the offending drug. Progression of lymphomatoid drug eruptions to true malignant lymphoma has been reported but is exceptional [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H373512113\"><span class=\"h3\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histology of drug reactions without systemic symptoms mimicking cutaneous T cell lymphoma shows dense band-like infiltrates of small lymphocytes, histiocytes, and usually eosinophils, admixed with variable numbers of medium-sized atypical T cells with pleomorphic or cerebriform nuclei <span class=\"nowrap\">and/or</span> variable numbers of CD30<sup>+</sup> blast cells. In most cases these atypical cells have a CD4<sup>+</sup> T-cell phenotype [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/31\" class=\"abstract_t\">31</a>]. Exocytosis of T cells is variable, and in some cases pseudo-Pautrier's micro-abscesses containing small T cells, CD1a<sup>+</sup> Langerhans cells, and sometimes eosinophils may be observed.</p><p class=\"headingAnchor\" id=\"H373512119\"><span class=\"h3\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clonal T-cell receptor (TCR) gene rearrangements have been found in a small number of lymphomatoid drug reactions [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/25,31\" class=\"abstract_t\">25,31</a>]. In most cases, a polyclonal pattern is present.</p><p class=\"headingAnchor\" id=\"H373512131\"><span class=\"h1\">IDIOPATHIC (SOLITARY) T CELL PSEUDOLYMPHOMA</span></p><p class=\"headingAnchor\" id=\"H53030134\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Idiopathic pseudo-T-cell lymphomas usually present as a solitary nodule or plaque most commonly located on the trunk or head (<a href=\"image.htm?imageKey=DERM%2F103522\" class=\"graphic graphic_picture graphicRef103522 \">picture 5</a>). Occasionally, two or more lesions may be present.</p><p class=\"headingAnchor\" id=\"H373512144\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Idiopathic pseudo-T-cell lymphomas may show two distinct histologic patterns [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32,33\" class=\"abstract_t\">32,33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Superficial band-like pattern simulating plaque-stage mycosis fungoides (MF) &ndash; These lesions show a dense superficial infiltrate characteristically showing sharply demarcated lateral and lower borders, and no or only focal infiltration of the epidermis (<a href=\"image.htm?imageKey=DERM%2F103531%7EDERM%2F103532\" class=\"graphic graphic_picture graphicRef103531 graphicRef103532 \">picture 6A-B</a>). (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">Nodular/diffuse</span> pattern simulating tumor-stage MF or a peripheral T cell lymphoma, not otherwise specified (PTCL, NOS) &ndash; These lesions show dense, diffuse or nodular infiltrates within the dermis with a tendency to infiltrate the subcutis (<a href=\"image.htm?imageKey=DERM%2F103537\" class=\"graphic graphic_picture graphicRef103537 \">picture 7</a>). Epidermotropism is generally mild or absent. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified&quot;</a>.)</p><p/><p>Both types of lesions show a predominance of small to medium-sized CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>-</sup>, and CD30<sup>-</sup> pleomorphic T cells. A small proportion of medium-sized to large pleomorphic cells may be present [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32\" class=\"abstract_t\">32</a>]. Characteristically, scattered medium-sized to large atypical T cells typically express programmed death-1 (PD-1), Bcl-6, and CXCL13, suggesting a common follicular helper T-cell phenotype (<a href=\"image.htm?imageKey=DERM%2F103538\" class=\"graphic graphic_picture graphicRef103538 \">picture 8</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/34,35\" class=\"abstract_t\">34,35</a>]. Scattered large B cells may be surrounded by PD-1<sup>+</sup> T cells forming rosettes [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/35\" class=\"abstract_t\">35</a>]. The proliferative rate is generally low. A considerable admixture of reactive CD8<sup>+</sup> T cells, CD20<sup>+</sup> B cells, plasma cells, and histiocytes, including multinucleated giant cells, can also be observed.</p><p class=\"headingAnchor\" id=\"H53030140\"><span class=\"h2\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clonal T-cell receptor (TCR) gene rearrangements are commonly found in idiopathic T cell pseudolymphomas [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32,36\" class=\"abstract_t\">32,36</a>]. In one study using the BIOMED-2 protocol [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/37\" class=\"abstract_t\">37</a>], clonal TCR gene rearrangements were detected in 6 of 9 cases with a superficial band-like pattern and 9 of 12 cases with a nodular to diffuse pattern [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/35\" class=\"abstract_t\">35</a>].</p><p class=\"headingAnchor\" id=\"H373512150\"><span class=\"h2\">Differential diagnosis</span></p><p class=\"headingAnchor\" id=\"H373512158\"><span class=\"h3\">Other types of T cell pseudolymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dense atypical band-like infiltrates can also be found in other types of cutaneous pseudo-T-cell lymphomas, such as lymphomatoid drug reactions without systemic symptoms [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32,35\" class=\"abstract_t\">32,35</a>]. A history of exposure to a high-risk medication (eg, antiepileptic drugs) and the resolution of the skin lesions after withdrawal of the offending drug help differentiate lymphomatoid drug reaction from idiopathic T cell pseudolymphoma.</p><p class=\"headingAnchor\" id=\"H373512164\"><span class=\"h3\">Mycosis fungoides</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Differentiation between idiopathic pseudo-T-cell lymphomas and <span class=\"nowrap\">patch/plaque</span> MF is generally not difficult, but requires a careful clinicopathologic correlation [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/1\" class=\"abstract_t\">1</a>]. Idiopathic pseudo-T-cell lymphomas usually present with a solitary lesion mainly on the trunk (<a href=\"image.htm?imageKey=DERM%2F103522\" class=\"graphic graphic_picture graphicRef103522 \">picture 5</a>), whereas early-stage MF usually presents with patches and plaques preferentially on non-sun-exposed skin areas, such as the trunk and buttocks (<a href=\"image.htm?imageKey=DERM%2F60650\" class=\"graphic graphic_picture graphicRef60650 \">picture 9</a>).</p><p>Histologic differences between early-stage MF and idiopathic pseudo-T-cell lymphomas include a nearly complete absence of epidermotropism, presence of scattered PD-1<sup>+</sup> medium-sized to large atypical T cells, and a considerable admixture of reactive CD8<sup>+</sup> T cells, CD20<sup>+</sup> B cells, plasma cells, and histiocytes. The same cellular composition is observed in nodular pseudo-T-cell lymphomas and facilitates the differentiation from tumor-stage MF and PTCL, NOS.</p><p>Moreover, the presence of more than 30 percent large T cells, the demonstration of loss of pan-T-cell markers, a high proportion of proliferating cells (MIB-1<sup>+</sup>), and the clinical finding of concurrent patches and plaques strongly suggest a diagnosis of malignant lymphoma.</p><p class=\"headingAnchor\" id=\"H373512170\"><span class=\"h3\">Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical, histologic, and immunophenotypical characteristics of nodular idiopathic pseudo-T-cell lymphomas are very similar, if not identical, to those of primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> pleomorphic T cell lymphoma (PCSM-TCL) presenting with a solitary lesion. Histologic similarities include the presence of scattered medium-sized to large CD4<sup>+</sup> T cells expressing PD-1, many admixed B cells, CD8<sup>+</sup> T cells, and histiocytes [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/35,38,39\" class=\"abstract_t\">35,38,39</a>]. Clonal T cells are found in both conditions and are no longer considered a useful differential diagnostic criterion [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/35\" class=\"abstract_t\">35</a>]. </p><p>In the 2016 revision of the World Health Organization (WHO) classification for tumors of hematopoietic and lymphoid tissues expected to be published in 2017, these lesions will be collectively termed primary cutaneous CD4<sup>+</sup> <span class=\"nowrap\">small/medium</span> T cell lymphoproliferative disorder [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/40\" class=\"abstract_t\">40</a>]. (See <a href=\"topic.htm?path=classification-of-primary-cutaneous-lymphomas\" class=\"medical medical_review\">&quot;Classification of primary cutaneous lymphomas&quot;</a>.)</p><p>Rare cases of PCSM-TCL that present with generalized skin lesions or rapidly growing bulky tumors, or show a high proliferative fraction, or a very low percentage of admixed CD8<sup>+</sup> T cells, may have a more aggressive clinical course and are better considered as primary cutaneous PTCL, NOS [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H373512176\"><span class=\"h2\">Treatment and prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Idiopathic T cell pseudolymphomas may resolve spontaneously after skin biopsy [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32\" class=\"abstract_t\">32</a>]. Persistent lesions can be treated with intralesional steroids or surgical excision, or in rare instances with radiotherapy [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32,36\" class=\"abstract_t\">32,36</a>].</p><p>Recurrence of idiopathic pseudo-T-cell lymphoma is uncommon. Patients have an excellent long-term prognosis and do not require further examinations or staging [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32,36\" class=\"abstract_t\">32,36</a>].</p><p class=\"headingAnchor\" id=\"H373512182\"><span class=\"h1\">LYMPHOMATOID KERATOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymphomatoid keratosis is clinically and histologically very similar to the superficial MF-like type of idiopathic pseudo-T-cell lymphoma [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/42\" class=\"abstract_t\">42</a>]. It presents in older adults as a solitary scaly plaque that resembles seborrheic keratosis or actinic keratosis.</p><p>Histologic examination shows a dense band-like infiltrate, often with prominent epidermotropism mimicking MF. As in idiopathic pseudo-T-cell lymphoma, there is a considerable admixture of small to medium-sized pleomorphic T cells with CD20<sup>+</sup> B cells. Clonal T cells have been found in about half of the cases [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"headingAnchor\" id=\"H373512188\"><span class=\"h1\">HIV AND OTHER IMMUNODEFICIENCY-RELATED CD8+ CUTANEOUS PSEUDOLYMPHOMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV-related CD8<sup>+</sup> cutaneous pseudolymphoma is an inflammatory process resulting from a massive infiltration of the skin by activated, oligoclonal, HIV-specific CD8<sup>+</sup> lymphocytes [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/43\" class=\"abstract_t\">43</a>]. It has been reported in severely immunocompromised patients and was more common before the introduction of potent antiretroviral therapy (ART).</p><p>Patients present with pruritic erythematous plaques and nodules located in sun-exposed skin areas that may progress to generalized erythroderma [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Histologic examination shows a dense infiltrate of cytotoxic CD8<sup>+</sup> T cells in the superficial dermis with variable degrees of epidermotropism and folliculotropism. Cellular atypia is usually mild and T-cell clonality is generally not detected.</p><p>Regression of the skin lesion after the initiation of ART has been reported [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/45\" class=\"abstract_t\">45</a>]. One patient with persistent lesions despite ART was successfully treated with low-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/46\" class=\"abstract_t\">46</a>].</p><p>Similar atypical CD8<sup>+</sup> T-cell infiltrates, often associated with considerable numbers of histiocytes <span class=\"nowrap\">and/or</span> granulomas, have been reported in patients with various types of immunodeficiency presenting with generalized papulonodular skin lesions [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/47-49\" class=\"abstract_t\">47-49</a>]. In most cases, clonal T cells can be detected. In patients, particularly children, presenting with skin lesions showing clonal CD8<sup>+</sup> T-cell infiltrates, thorough investigations to detect a possible immunodeficiency should be performed.</p><p class=\"headingAnchor\" id=\"H373512194\"><span class=\"h1\">OTHER MIMICKERS OF EARLY-STAGE MYCOSIS FUNGOIDES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several benign inflammatory dermatoses may in rare instances show histologic features simulating early-stage MF. These include, among others, lichen sclerosus, lichen <span class=\"nowrap\">aureus/pigmented</span> purpuric dermatosis, and early (inflammatory) stage of vitiligo [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/50-53\" class=\"abstract_t\">50-53</a>].</p><p>Common histopathologic findings include a superficial band-like lymphoid infiltrate and variable infiltration of the lower layers of the epidermis. The infiltrates are predominantly composed of small, sometimes slightly atypical T cells, and clonal T-cell receptor (TCR) gene rearrangements can be detected in some cases. The relationship between pigmented purpuric dermatosis and MF is discussed elsewhere. (See <a href=\"topic.htm?path=pigmented-purpuric-dermatoses-capillaritis#H22917793\" class=\"medical medical_review\">&quot;Pigmented purpuric dermatoses (capillaritis)&quot;, section on 'Relationship to mycosis fungoides'</a>.)</p><p>A careful clinicopathologic correlation is essential and in most cases sufficient to make a correct diagnosis.</p><p class=\"headingAnchor\" id=\"H373512200\"><span class=\"h1\">MIMICKERS OF PRIMARY CUTANEOUS CD30+ LYMPHOPROLIFERATIVE DISORDERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CD30 is typically expressed by the neoplastic T cells of primary cutaneous CD30<sup>+</sup> lymphoproliferative diseases such as lymphomatoid papulosis and cutaneous anaplastic large-cell lymphoma. However, a wide variety of inflammatory and infectious skin diseases may contain CD30<sup>+</sup> cells [<a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/26\" class=\"abstract_t\">26</a>]. These include viral infections (eg, orf, milker's nodule, herpes virus infections, HIV infections), reactions to arthropod bites, nodular scabies, drug eruptions, and atopic dermatitis. (See <a href=\"topic.htm?path=lymphomatoid-papulosis#H18325888\" class=\"medical medical_review\">&quot;Lymphomatoid papulosis&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H57821762\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous T cell pseudolymphomas include clinicopathologic entities that mimic early <span class=\"nowrap\">patch/plaque-stage</span> mycosis fungoides (MF) or tumor-stage MF or peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Examples of cutaneous T cell pseudolymphomas simulating early-stage MF include lymphomatoid contact dermatitis, lymphomatoid drug eruptions, and actinic reticuloid. (See <a href=\"#H373511903\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Actinic reticuloid is a severe photosensitivity reaction with histologic features suggesting mycosis fungoides or S&eacute;zary syndrome. The predominance of CD8<sup>+</sup> T-cell phenotype and a normal or even reversed CD4:CD8 ratio in the peripheral blood help distinguish actinic reticuloid from a true lymphoma. (See <a href=\"#H373512003\" class=\"local\">'Actinic reticuloid'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rare cases of allergic contact dermatitis may show clinical and histologic features simulating early-stage MF. A positive patch test to a relevant allergen and the resolution of the skin lesion with avoidance of the offending allergen support the diagnosis of allergic contact dermatitis. (See <a href=\"#H373512057\" class=\"local\">'Lymphomatoid contact dermatitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some patients with drug reaction with eosinophilia and systemic symptoms (DRESS), a severe drug reaction predominantly caused by antiepileptics, <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a>, sulfonamides, and antibiotics, may have clinical, histologic, and hematologic findings mimicking mycosis <span class=\"nowrap\">fungoides/S&eacute;zary</span> syndrome. The resolution of symptoms after withdrawal of the offending drug supports the diagnosis. (See <a href=\"#H373512063\" class=\"local\">'Lymphomatoid drug reaction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic pseudo-T-cell lymphomas usually present as a solitary nodule or plaque most commonly located on the trunk or head. They may have a band-like superficial pattern or a nodular or diffuse pattern. (See <a href=\"#H373512131\" class=\"local\">'Idiopathic (solitary) T cell pseudolymphoma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The absence of epidermotropism, presence of scattered PD-1<sup>+</sup> atypical T cells, and a considerable admixture of reactive CD8<sup>+</sup> T cells, CD20<sup>+</sup> B cells, plasma cells, and histiocytes in both superficial band-like and nodular pseudo-T-cell lymphomas facilitates the differentiation of idiopathic pseudo-T-cell lymphomas from MF and PTCL, NOS. (See <a href=\"#H373512150\" class=\"local\">'Differential diagnosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/1\" class=\"nounderline abstract_t\">Rijlaarsdam JU, Willemze R. Cutaneous pseudolymphomas: classification and differential diagnosis. Semin Dermatol 1994; 13:187.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/2\" class=\"nounderline abstract_t\">Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol 1998; 38:877.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/3\" class=\"nounderline abstract_t\">Ive FA, Magnus IA, Warin RP, Jones EW. &quot;Actinic reticuloid&quot;; a chronic dermatosis associated with severe photosensitivity and the histological resemblance to lymphoma. Br J Dermatol 1969; 81:469.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/4\" class=\"nounderline abstract_t\">Paek SY, Lim HW. Chronic actinic dermatitis. Dermatol Clin 2014; 32:355.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/5\" class=\"nounderline abstract_t\">Toonstra J, Henquet CJ, van Weelden H, et al. Actinic reticuloid. A clinical photobiologic, histopathologic, and follow-u study of 16 patients. J Am Acad Dermatol 1989; 21:205.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/6\" class=\"nounderline abstract_t\">Sidiropoulos M, Deonizio J, Martinez-Escala ME, et al. Chronic actinic dermatitis/actinic reticuloid: a clinicopathologic and immunohistochemical analysis of 37 cases. Am J Dermatopathol 2014; 36:875.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/7\" class=\"nounderline abstract_t\">Yap LM, Foley P, Crouch R, Baker C. Chronic actinic dermatitis: a retrospective analysis of 44 cases referred to an Australian photobiology clinic. Australas J Dermatol 2003; 44:256.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/8\" class=\"nounderline abstract_t\">Agar N, Morris S, Russell-Jones R, et al. Case report of four patients with erythrodermic cutaneous T-cell lymphoma and severe photosensitivity mimicking chronic actinic dermatitis. Br J Dermatol 2009; 160:698.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/9\" class=\"nounderline abstract_t\">Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/10\" class=\"nounderline abstract_t\">Bakels V, van Oostveen JW, Preesman AH, et al. Differentiation between actinic reticuloid and cutaneous T cell lymphoma by T cell receptor gamma gene rearrangement analysis and immunophenotyping. J Clin Pathol 1998; 51:154.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/11\" class=\"nounderline abstract_t\">Orbaneja JG, Diez LI, Lozano JL, Salazar LC. Lymphomatoid contact dermatitis: a syndrome produced by epicutaneous hypersensitivity with clinical features and a histopathologic picture similar to that of mycosis fungoides. Contact Dermatitis 1976; 2:139.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/12\" class=\"nounderline abstract_t\">Knackstedt TJ, Zug KA. T cell lymphomatoid contact dermatitis: a challenging case and review of the literature. Contact Dermatitis 2015; 72:65.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/13\" class=\"nounderline abstract_t\">Kardaun SH, Scheffer E, Vermeer BJ. Drug-induced pseudolymphomatous skin reactions. Br J Dermatol 1988; 118:545.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/14\" class=\"nounderline abstract_t\">Rijlaarsdam U, Scheffer E, Meijer CJ, et al. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24:216.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/15\" class=\"nounderline abstract_t\">Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma with CD-30 positive cells. J Am Acad Dermatol 1998; 38:806.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/16\" class=\"nounderline abstract_t\">Kabashima R, Orimo H, Hino R, et al. CD30-positive T-cell pseudolymphoma induced by amlodipine. J Eur Acad Dermatol Venereol 2008; 22:1522.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/17\" class=\"nounderline abstract_t\">Sawada Y, Yoshiki R, Kawakami C, et al. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol 2010; 90:521.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/18\" class=\"nounderline abstract_t\">Pulitzer MP, Nolan KA, Oshman RG, Phelps RG. CD30+ lymphomatoid drug reactions. Am J Dermatopathol 2013; 35:343.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/19\" class=\"nounderline abstract_t\">Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol 1996; 27:125.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/20\" class=\"nounderline abstract_t\">Luelmo Aguilar J, Mieras Barcel&oacute; C, Mart&iacute;n-Urda MT, et al. Generalized cutaneous B-cell pseudolymphoma induced by neuroleptics. Arch Dermatol 1992; 128:121.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/21\" class=\"nounderline abstract_t\">Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/22\" class=\"nounderline abstract_t\">D'Incan M, Souteyrand P, Bignon YJ, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of S&eacute;zary syndrome. Arch Dermatol 1992; 128:1371.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/23\" class=\"nounderline abstract_t\">Reeder MJ, Wood GS. Drug-induced pseudo-Sezary syndrome: a case report and literature review. Am J Dermatopathol 2015; 37:83.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/24\" class=\"nounderline abstract_t\">Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, et al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol 2015; 173:50.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/25\" class=\"nounderline abstract_t\">Callot V, Roujeau JC, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996; 132:1315.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/26\" class=\"nounderline abstract_t\">Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol 2008; 35:1100.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/27\" class=\"nounderline abstract_t\">Jung J, Levin EC, Jarrett R, et al. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147:992.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/28\" class=\"nounderline abstract_t\">Saeed SA, Bazza M, Zaman M, Ryatt KS. Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad Med J 2000; 76:577.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/29\" class=\"nounderline abstract_t\">Fukamachi S, Sugita K, Sawada Y, et al. Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol 2009; 19:292.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/30\" class=\"nounderline abstract_t\">Sangueza OP, Cohen DE, Calciano A, et al. Mycosis fungoides induced by phenytoin. Eur J Dermatol 1993; 3:474.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/31\" class=\"nounderline abstract_t\">Magro CM, Crowson AN, Kovatich AJ, Burns F. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol 2003; 34:119.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/32\" class=\"nounderline abstract_t\">Rijlaarsdam JU, Scheffer E, Meijer CJ, Willemze R. Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients. Cancer 1992; 69:717.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/33\" class=\"nounderline abstract_t\">Smolle J, Torne R, Soyer HP, Kerl H. Immunohistochemical classification of cutaneous pseudolymphomas: delineation of distinct patterns. J Cutan Pathol 1990; 17:149.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/34\" class=\"nounderline abstract_t\">Rodr&iacute;guez Pinilla SM, Roncador G, Rodr&iacute;guez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 2009; 33:81.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/35\" class=\"nounderline abstract_t\">Cetin&ouml;zman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012; 36:109.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/36\" class=\"nounderline abstract_t\">Leinweber B, Beltraminelli H, Kerl H, Cerroni L. Solitary small- to medium-sized pleomorphic T-cell nodules of undetermined significance: clinical, histopathological, immunohistochemical and molecular analysis of 26 cases. Dermatology 2009; 219:42.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/37\" class=\"nounderline abstract_t\">Langerak AW, Groenen PJ, Br&uuml;ggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012; 26:2159.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/38\" class=\"nounderline abstract_t\">Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol 2009; 31:317.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/39\" class=\"nounderline abstract_t\">Alberti-Violetti S, Torres-Cabala CA, Talpur R, et al. Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. J Cutan Pathol 2016; 43:1121.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/40\" class=\"nounderline abstract_t\">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/41\" class=\"nounderline abstract_t\">Garcia-Herrera A, Colomo L, Cam&oacute;s M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008; 26:3364.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/42\" class=\"nounderline abstract_t\">Arai E, Shimizu M, Tsuchida T, et al. Lymphomatoid keratosis: an epidermotropic type of cutaneous lymphoid hyperplasia: clinicopathological, immunohistochemical, and molecular biological study of 6 cases. Arch Dermatol 2007; 143:53.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/43\" class=\"nounderline abstract_t\">Bachelez H, Hadida F, Gorochov G. Massive infiltration of the skin by HIV-specific cytotoxic CD8+ T cells. N Engl J Med 1996; 335:61.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/44\" class=\"nounderline abstract_t\">Guitart J, Variakojis D, Kuzel T, Rosen S. Cutaneous CD8 T cell infiltrates in advanced HIV infection. J Am Acad Dermatol 1999; 41:722.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/45\" class=\"nounderline abstract_t\">Schartz NE, De La Blanchardi&eacute;re A, Alaoui S, et al. Regression of CD8+ pseudolymphoma after HIV antiviral triple therapy. J Am Acad Dermatol 2003; 49:139.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/46\" class=\"nounderline abstract_t\">Ingen-Housz-Oro S, Sbidian E, Ortonne N, et al. HIV-related CD8+ cutaneous pseudolymphoma: efficacy of methotrexate. Dermatology 2013; 226:15.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/47\" class=\"nounderline abstract_t\">Marzano AV, Berti E, Alessi E, Caputo R. Clonal CD8 infiltration of the skin in common variable immunodeficiency: a prelymphomatous stage? J Am Acad Dermatol 2001; 44:710.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/48\" class=\"nounderline abstract_t\">Schuetz C, Huck K, Gudowius S, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med 2008; 358:2030.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/49\" class=\"nounderline abstract_t\">Gammon B, Robson A, Deonizio J, et al. CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency. J Am Acad Dermatol 2014; 71:555.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/50\" class=\"nounderline abstract_t\">Citarella L, Massone C, Kerl H, Cerroni L. Lichen sclerosus with histopathologic features simulating early mycosis fungoides. Am J Dermatopathol 2003; 25:463.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/51\" class=\"nounderline abstract_t\">Fink-Puches R, Wolf P, Kerl H, Cerroni L. Lichen aureus: clinicopathologic features, natural history, and relationship to mycosis fungoides. Arch Dermatol 2008; 144:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/52\" class=\"nounderline abstract_t\">Horn TD, Abanmi A. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am J Dermatopathol 1997; 19:400.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-t-cell-pseudolymphomas/abstract/53\" class=\"nounderline abstract_t\">Petit T, Cribier B, Bagot M, Wechsler J. Inflammatory vitiligo-like macules that simulate hypopigmented mycosis fungoides. Eur J Dermatol 2003; 13:410.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15723 Version 5.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H57821762\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H373511903\" id=\"outline-link-H373511903\">INTRODUCTION</a></li><li><a href=\"#H373512003\" id=\"outline-link-H373512003\">ACTINIC RETICULOID</a><ul><li><a href=\"#H25276800\" id=\"outline-link-H25276800\">Pathology</a></li><li><a href=\"#H373512039\" id=\"outline-link-H373512039\">Diagnosis</a></li><li><a href=\"#H85106212\" id=\"outline-link-H85106212\">Differential diagnosis</a></li></ul></li><li><a href=\"#H373512057\" id=\"outline-link-H373512057\">LYMPHOMATOID CONTACT DERMATITIS</a></li><li><a href=\"#H373512063\" id=\"outline-link-H373512063\">LYMPHOMATOID DRUG REACTION</a><ul><li><a href=\"#H57372718\" id=\"outline-link-H57372718\">Drug-induced pseudolymphoma syndrome (DRESS mimicking CTCL)</a></li><li><a href=\"#H373512101\" id=\"outline-link-H373512101\">Drug eruptions without systemic symptoms simulating CTCL</a><ul><li><a href=\"#H373512107\" id=\"outline-link-H373512107\">- Clinical features</a></li><li><a href=\"#H373512113\" id=\"outline-link-H373512113\">- Pathology</a></li><li><a href=\"#H373512119\" id=\"outline-link-H373512119\">- Genetics</a></li></ul></li></ul></li><li><a href=\"#H373512131\" id=\"outline-link-H373512131\">IDIOPATHIC (SOLITARY) T CELL PSEUDOLYMPHOMA</a><ul><li><a href=\"#H53030134\" id=\"outline-link-H53030134\">Clinical features</a></li><li><a href=\"#H373512144\" id=\"outline-link-H373512144\">Pathology</a></li><li><a href=\"#H53030140\" id=\"outline-link-H53030140\">Genetics</a></li><li><a href=\"#H373512150\" id=\"outline-link-H373512150\">Differential diagnosis</a><ul><li><a href=\"#H373512158\" id=\"outline-link-H373512158\">- Other types of T cell pseudolymphoma</a></li><li><a href=\"#H373512164\" id=\"outline-link-H373512164\">- Mycosis fungoides</a></li><li><a href=\"#H373512170\" id=\"outline-link-H373512170\">- Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma</a></li></ul></li><li><a href=\"#H373512176\" id=\"outline-link-H373512176\">Treatment and prognosis</a></li></ul></li><li><a href=\"#H373512182\" id=\"outline-link-H373512182\">LYMPHOMATOID KERATOSIS</a></li><li><a href=\"#H373512188\" id=\"outline-link-H373512188\">HIV AND OTHER IMMUNODEFICIENCY-RELATED CD8+ CUTANEOUS PSEUDOLYMPHOMA</a></li><li><a href=\"#H373512194\" id=\"outline-link-H373512194\">OTHER MIMICKERS OF EARLY-STAGE MYCOSIS FUNGOIDES</a></li><li><a href=\"#H373512200\" id=\"outline-link-H373512200\">MIMICKERS OF PRIMARY CUTANEOUS CD30+ LYMPHOPROLIFERATIVE DISORDERS</a></li><li><a href=\"#H57821762\" id=\"outline-link-H57821762\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15723|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/101492\" class=\"graphic graphic_picture\">- Chronic actinic dermatitis</a></li><li><a href=\"image.htm?imageKey=DERM/101494\" class=\"graphic graphic_picture\">- Chronic actinic dermatitis dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/103382\" class=\"graphic graphic_picture\">- Actinic reticuloid histo</a></li><li><a href=\"image.htm?imageKey=DERM/103383\" class=\"graphic graphic_picture\">- Actinic reticuloid histo 2</a></li><li><a href=\"image.htm?imageKey=DERM/103512\" class=\"graphic graphic_picture\">- Lymphomatoid drug eruption</a></li><li><a href=\"image.htm?imageKey=DERM/103522\" class=\"graphic graphic_picture\">- CD4+ PCSM-TCL</a></li><li><a href=\"image.htm?imageKey=DERM/103531\" class=\"graphic graphic_picture\">- Idiopathic T cell pseudolymphoma histo</a></li><li><a href=\"image.htm?imageKey=DERM/103532\" class=\"graphic graphic_picture\">- Idiopathic T cell pseudolymphoma immunophenotype</a></li><li><a href=\"image.htm?imageKey=DERM/103537\" class=\"graphic graphic_picture\">- CD4+ PCSM-TCL histopathology 2</a></li><li><a href=\"image.htm?imageKey=DERM/103538\" class=\"graphic graphic_picture\">- CD4+ PCSM-TCL immunophenotype</a></li><li><a href=\"image.htm?imageKey=DERM/60650\" class=\"graphic graphic_picture\">- Mycosis fungoides patches</a></li></ul></li><li><div id=\"DERM/15723|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/102613\" class=\"graphic graphic_table\">- Cutaneous T and B pseudolymphomas</a></li><li><a href=\"image.htm?imageKey=DERM/86760\" class=\"graphic graphic_table\">- Drugs associated with DRESS</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=classification-of-primary-cutaneous-lymphomas\" class=\"medical medical_review\">Classification of primary cutaneous lymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-systemic-anaplastic-large-cell-lymphoma\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-sezary-syndrome\" class=\"medical medical_review\">Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-b-cell-pseudolymphomas\" class=\"medical medical_review\">Cutaneous B cell pseudolymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lymphomatoid-papulosis\" class=\"medical medical_review\">Lymphomatoid papulosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pigmented-purpuric-dermatoses-capillaritis\" class=\"medical medical_review\">Pigmented purpuric dermatoses (capillaritis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-cutaneous-t-cell-lymphomas-rare-subtypes\" class=\"medical medical_review\">Primary cutaneous T cell lymphomas, rare subtypes</a></li></ul></div></div>","javascript":null}